| Nov 1 |
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
| Oct 23 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 22 |
Akebia stock climbs 8% on dialysis provider supply agreement
|
| Oct 22 |
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
|
| Oct 15 |
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
|
| Oct 10 |
Akebia gains additional CMS reimbursement for end-stage renal disease drug Vafseo
|
| Oct 10 |
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
|
| Oct 9 |
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
| Oct 7 |
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
|
| Oct 5 |
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability
|
